The Global Cell & Gene Therapy Summit 2024 (CGT Summit 2024) was held as scheduled in Boston, the United States from July 8 to 10, 2024. The summit brought together pharmaceutical companies and research teams from well-known universities in the United States, Europe, Japan and other places, aiming to strengthen discussions between companies and between companies and academia on the current R&D hotspots, clinical applications and cooperation in the field of cell and gene therapy.

Beijing GeneCradle Technology Co., Ltd. (hereinafter referred to as "GeneCradle") demonstrated the progress of clinical trials in China of its independently developed gene therapy drugs GC101 for spinal muscular atrophy and GC301 for Pompe disease at this event. It also disclosed for the first time the early data of clinical trials of four representative AAV gene therapy drugs, which attracted the attention of the majority of guests. Participants from internationally renowned companies such as Novartis and BioMarin had a full discussion with Dr. Wang Xiaodong of GeneCradle on the content of the poster and showed great interest in the progress of GeneCradle's clinical trials in China.

About GeneCradle

Beijing GeneCradle Technology Co., Ltd. is a national high-tech enterprise with the development of gene therapy drugs mediated by AAV vector delivery technology as its core business. Its mission is to promote China's rare disease gene drugs from basic to clinical and market, benefiting patients and families. The company focuses on the development of gene therapy drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases and ophthalmic diseases. By promoting the development and clinical application of rare disease gene drugs, it has a deeper understanding of life and health, and has transitioned gene therapy technologies and products from rare diseases to the treatment and rehabilitation of chronic diseases and other major diseases.